Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SUPERNUS PHARMACEUTICALS, INC.

(SUPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Supernus Pharmaceuticals : Pharma Says Named New CFO After Incumbent Resigned to Join Another Company; Stock Slides

07/30/2021 | 12:10pm EDT


ę MT Newswires 2021
All news about SUPERNUS PHARMACEUTICALS, INC.
09/16EQS-ADHOC : Newron announces Half-Year 2021 results
DJ
09/16PRESS RELEASE : Newron announces Half-Year 2021 results
DJ
09/06EQS-ADHOC : Newron Receives Fourth Tranche from Financing Agreement with European Investme..
DJ
09/06PRESS RELEASE : Newron Receives Fourth Tranche from Financing Agreement with European Inve..
DJ
09/06EQS-ADHOC : Newron Initiates First Potentially Pivotal Study with Evenamide in Patients wi..
DJ
09/06PRESS RELEASE : Newron Initiates First Potentially Pivotal Study with Evenamide in Patient..
DJ
09/03SUPERNUS PHARMACEUTICALS : Announces Qelbree sNDA for Adult Indication Accepted for Review..
AQ
09/03Health Care Stocks Advance Pre-Bell Friday
MT
09/03SUPERNUS PHARMACEUTICALS : Announces Qelbree™ sNDA for Adult Indication Accepted for..
PU
09/03Supernus Pharmaceuticals, Inc. Announces Qelbree sNDA for Adult Indication Accepted for..
CI
More news
Analyst Recommendations on SUPERNUS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 561 M - -
Net income 2021 55,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 26,5x
Yield 2021 -
Capitalization 1 441 M 1 441 M -
Capi. / Sales 2021 2,57x
Capi. / Sales 2022 2,37x
Nbr of Employees 563
Free-Float 96,0%
Chart SUPERNUS PHARMACEUTICALS, INC.
Duration : Period :
Supernus Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUPERNUS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 27,11 $
Average target price 35,00 $
Spread / Average Target 29,1%
EPS Revisions
Managers and Directors
Jack A. Khattar President, CEO, Secretary & Director
Timothy C. Dec Chief Financial Officer & Senior Vice President
Charles W. Newhall Chairman
Padmanabh P. Bhatt Chief Scientific Officer & Senior Vice President
Frank Mottola Senior VP-Quality, GMP Operations & IT
Sector and Competitors